1,282 results on '"Gerds, A. T."'
Search Results
52. Interferons in the treatment of myeloproliferative neoplasms
53. Association between elevated white blood cell counts and thrombotic events in polycythemia vera: Analysis from REVEAL
54. MPN-103 A Real-World Evaluation of the Association Between Elevated Blood Counts and Thrombotic Events in Polycythemia Vera: Analysis of Data From the REVEAL Study
55. Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation
56. The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion
57. Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes
58. Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience
59. Longitudinal Safety of Luspatercept in the Treatment of Anemia in Patients with Myelofibrosis: Results from the ACE-536-MF-001 Study
60. Significance of the Apoptotic Regulators BAX, BCL2, BCL- XL and MCL1 in Newly Diagnosed AML
61. Successful Treatment of Recurrent Pericarditis With Rilonacept in Acute Promyelocytic Leukemia
62. Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials
63. Supplementary Figure S5 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
64. Supplementary Table S3 from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
65. Data from A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
66. MPN-574 Characteristics and Clinical Outcomes in Patients With Polycythemia Vera Receiving Ruxolitinib After Hydroxyurea: A Longitudinal Analysis From the Prospective Observational Study of Patients With Polycythemia Vera in US Clinical Practices Trial (REVEAL)
67. MPN-383 Healthcare Resource Utilization and Costs Associated With Transfusion Dependence and Anemia Severity in Patients With Myelofibrosis: A Retrospective Analysis of the Medicare Fee-for-Service Claims Data
68. POSTER: MPN-383 Healthcare Resource Utilization and Costs Associated With Transfusion Dependence and Anemia Severity in Patients With Myelofibrosis: A Retrospective Analysis of the Medicare Fee-for-Service Claims Data
69. POSTER: MPN-574 Characteristics and Clinical Outcomes in Patients With Polycythemia Vera Receiving Ruxolitinib After Hydroxyurea: A Longitudinal Analysis From the Prospective Observational Study of Patients With Polycythemia Vera in US Clinical Practices Trial (REVEAL)
70. POSTER: MDS 684 Clonal Hematopoiesis of Indeterminate Potential (CHIP) Clinic: The Cleveland Clinic Experience
71. POSTER: MPN-070 Real-World Clinical Outcomes in Patients With Myelofibrosis (MF) Previously Treated With Ruxolitinib (RUX)
72. MPN-404 Safety and Efficacy of Luspatercept for the Treatment of Anemia in Patients With Myelofibrosis: Results From the ACE-536-MF-001 Study
73. Real-World Use of Fedratinib for Myelofibrosis Following Prior Ruxolitinib Failure: Patient Characteristics, Treatment Patterns, and Clinical Outcomes
74. Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
75. MDS-684 Clonal Hematopoiesis of Indeterminate Potential (CHIP) Clinic: The Cleveland Clinic Experience
76. MPN-070 Real-World Clinical Outcomes in Patients With Myelofibrosis (MF) Previously Treated With Ruxolitinib (RUX)
77. POSTER: MPN-404 Safety and Efficacy of Luspatercept for the Treatment of Anemia in Patients With Myelofibrosis: Results From the ACE-536-MF-001 Study
78. Music Therapy for Symptom Management After Autologous Stem Cell Transplantation: Results From a Randomized Study
79. Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes
80. Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome
81. Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia
82. Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study
83. S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX
84. S167: EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY
85. P1044: REDUCTION IN RED BLOOD CELL TRANSFUSION BURDEN: A NOVEL LONGITUDINAL TIME-DEPENDENT ANALYSIS IN PATIENTS WITH TRANSFUSION-DEPENDENT MYELOFIBROSIS TREATED WITH MOMELOTINIB
86. P1030: SPLEEN VOLUME REDUCTION PREDICTS SURVIVAL IN MYELOFIBROSIS PATIENTS ON PACRITINIB BUT NOT BEST AVAILABLE THERAPY: PERSIST-2 LANDMARK OVERALL SURVIVAL ANALYSIS
87. P1032: CHARACTERISTICS AND CLINICAL OUTCOMES IN PATIENTS (PTS) WITH POLYCYTHEMIA VERA (PV) RECEIVING RUXOLITINIB (RUX) AFTER HYDROXYUREA (HU): A LONGITUDINAL ANALYSIS FROM REVEAL
88. A Phase Ib Trial of AVID200, a TGFβ 1/3 Trap, in Patients with Myelofibrosis
89. Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes
90. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy
91. Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing
92. Mitigating Fear and Loathing in Managing Acute Myeloid Leukemia
93. Social Media in Hematology in 2017: Dystopia, Utopia, or Somewhere In-between?
94. Patient-Reported Outcomes in Myelodysplastic Syndromes and MDS/MPN Overlap Syndromes: Stepping Onto the Stage with Changing Times
95. The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies
96. Momelotinib long-term safety and survival in myelofibrosis : integrated analysis of phase 3 randomized-controlled trials
97. Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis
98. A Multicenter Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia
99. Abstract A062: Age-, sex-, and race-related disparities in receipt of HypomethyLating Agents (HMA) for the treatment of myelodysplastic syndrome (MDS)
100. Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.